Alnylam

Amvuttra
Mar 17, 2025
Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space
All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…
Read more
Alnylam Pharmaceuticals, Inc.
Mar 13, 2024
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
– Family Health History Road Trip Program Aims to Inspire Conversations About Health History and Empower Families to Take Control of Their Health ––…
Read more
Subscribe to